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Abstract
 
The major histocompatibility complex class Ib protein, Qa-1
 
b
 
, serves as a ligand for murine
CD94/NKG2A natural killer (NK) cell inhibitory receptors. The Qa-1
 
b
 
 peptide-binding site is
predominantly occupied by a single nonameric peptide, Qa-1 determinant modifier (Qdm),
derived from the leader sequence of H-2D and L molecules. Five anchor residues were identi-
fied in this study by measuring the peptide-binding affinities of substituted Qdm peptides in
experiments with purified recombinant Qa-1
 
b
 
. A candidate peptide-binding motif was deter-
mined by sequence analysis of peptides eluted from Qa-1 that had been folded in the presence
of random peptide libraries or pools of Qdm derivatives randomized at specific anchor posi-
tions. The results indicate that Qa-1
 
b
 
 can bind a diverse repertoire of peptides but that Qdm
has an optimal primary structure for binding Qa-1
 
b
 
. Flow cytometry experiments with Qa-1
 
b
 
tetramers and NK target cell lysis assays demonstrated that CD94/NKG2A discriminates be-
tween Qa-1
 
b
 
 complexes containing peptides with substitutions at nonanchor positions P4, P5,
or P8. Our findings suggest that it may be difficult for viruses to generate decoy peptides that
mimic Qdm and raise the possibility that competitive replacement of Qdm with other peptides
may provide a novel mechanism for activation of NK cells.
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Introduction
 
Qa-1
 
b
 
 is a nonclassical MHC class I molecule encoded by
the 
 
T23
 
 gene in the T region of the H-2 complex in mice
(1–4). Early studies demonstrated that Qa-1 can be directly
recognized by alloreactive cytolytic CD8
 
1
 
 T cells (5, 6).
Like most class Ib molecules, Qa-1 is relatively nonpoly-
morphic (7, 8). It is expressed in a wide range of tissues (3,
9) but cell-surface expression appears to be low and the cel-
lular half-life is relatively short (4). A series of studies on the
specificity of Qa-1–specific alloreactive T cells led to the
discovery that a major fraction of Qa-1–restricted CTLs
recognize a nine–amino acid peptide (AMAPRTLLL) from
the leader sequence of H-2D or L molecules (9–11). This
peptide is termed Qa-1 determinant modifier (Qdm).
 
1
 
Recognition by a subset of CTLs was sensitive to a poly-
morphism mapping to H-2D, with Val instead of Ala in
the third position in the D
 
k
 
 leader peptide. Presentation of
Qdm by Qa-1 was shown to be dependent on the trans-
porter associated with antigen processing (TAP) (10, 11).
Subsequent peptide elution studies demonstrated that the
 
predominant peptide associated with Qa-1 on mitogen-
activated T cells and transfected fibroblasts was Qdm (12, 13).
Despite evidence that Qa-1 molecules are dominantly
loaded with a single peptide, Qdm, several studies suggest
that Qa-1 can bind and present other antigens to T cells.
Vidovic et al. reported that recognition of the copolymer
Glu-50-Tyr-50 by a 
 
g/d
 
 T cell hybridoma was blocked by
 
J.R. Kraft and R.E. Vance contributed equally to this work.
Address correspondence to Peter E. Jensen, Department of Pathology
and Laboratory Medicine, Rm. 7313 WMRB, Emory University School
of Medicine, Atlanta, GA 30322. Phone: 404-727-3658; Fax: 404-727-
5764; E-mail: pjensen@bimcore.emory.edu
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; hsp, heat shock
protein; Qdm, Qa-1 determinant modifier; TAP, transporter associated
with antigen processing. 
614
 
Peptide Specificity in Recognition of Qa-1 by NK Cells
 
anti–Qa-1 Abs (14). Imani and Soloski demonstrated that a
tryptic digest of 
 
Mycobacterium bovis
 
 heat shock protein (hsp)
65 could stabilize Qa-1 expression on the surface of trans-
fected cells, suggesting that Qa-1 may be capable of bind-
ing an hsp-derived peptide(s) (15). Recent studies have
demonstrated that CD8
 
1
 
 CTLs are generated in mice after
infection with 
 
Salmonella typhimurium
 
 with specificity for a
nine–amino acid epitope in bacterial GroEL and cross-
reactivity with a corresponding mouse hsp60 peptide (16,
17). Qa-1–restricted CD8
 
1
 
 T cells with specificity for 
 
Lis-
teria monocytogenes
 
 have also been demonstrated, but the
epitope(s) remain to be defined (18, 19). We previously re-
ported the characterization of Qa-1
 
b
 
–restricted T cell hy-
bridomas derived from low-responder H-2
 
b
 
 mice immu-
nized with pork insulin (20). These T cells recognized an
insulin B chain determinant generated though a TAP-inde-
pendent processing pathway. Finally, Qa-1–restricted regu-
latory CD8
 
1
 
 T cells have been described with the capacity
to specifically kill activated V
 
b
 
8
 
1
 
 T cells (21, 22). These T
cells, induced by vaccination with V
 
b
 
8
 
1
 
 T cells or staphy-
lococcal enterotoxin B injection, presumably recognize T
cell receptor–derived peptides presented by Qa-1. These
various observations raise the possibility that Qa-1 may
have a capacity to bind and present a diverse repertoire of
peptides. However, the range of peptides that can be pre-
sented is uncertain and the Qa-1 peptide–binding motif has
not been defined.
Recent studies have shown that Qa-1 has an important
function as the dominant and possibly exclusive ligand for
murine C-type lectin family NK cell receptors, CD94/
NKG2 (23–26). Heterodimers of NKG2 family members
with CD94 recognize HLA-E in humans (27–29). Like
Qa-1, HLA-E appears to bind predominantly to certain
peptides derived from class I leader sequences (30, 31). In
addition, these two proteins have Ser at the normally con-
served positions 143 and 147 instead of Thr and Trp, re-
spectively, which are found in other class I molecules. De-
spite these shared features, Qa-1 and HLA-E are not
obvious orthologues based on sequence comparison. HLA-E
cell surface expression appears to be dependent on TAP
function and coexpression of a class I molecule containing
an appropriate leader sequence to serve as a source of pep-
tide (31, 32). In contrast, Qa-1 can be expressed in the ab-
sence of TAP and cell surface Qa-1 is not further stabilized
in TAP-deficient cells by exogenous Qdm peptide (23).
This finding is consistent with the idea that Qa-1 may have
a capacity to bind peptides other than Qdm through a
TAP-independent mechanism. Alternatively, Qa-1 may be
expressed without bound peptide; empty Qa-1 molecules
could be unusually stable.
The cytoplasmic domains of human and mouse NKG2A
contain immunoreceptor tyrosine-based inhibitory motifs,
and CD94/NKG2A heterodimers have been shown to in-
hibit NK cell function in the presence of HLA-E or Qa-1
ligand (23, 27–29, 33). Human NKG2C and NKG2E lack
immunoreceptor tyrosine-based inhibitory motifs, and at
least CD94/NKG2C has a capacity to activate NK cells
through association with the small signaling homodimer,
 
DAP12 (34). Mouse homologues of these activating recep-
tors have been identified, and they share specificity with
the CD94/NKG2A inhibitory receptor for Qa-1 (25).
NKG2C and NKG2E mRNA is considerably less abun-
dant than that encoding NKG2A in mouse NK cells, but
the distribution of activating and inhibitory receptors on
NK cell populations remains to be characterized. Several
studies suggest that human CD94/NKG2 receptors may
have a capacity to discriminate between HLA-E complexes
containing different leader sequence–derived peptides (35–
37). The molecular basis of specificity for leader peptides
and functional implications remain to be characterized. We
previously reported that Qa-1 molecules expressed in
TAP-deficient cells were unable to inhibit NK cell func-
tion unless exogenous Qdm peptide was provided (23).
This indicated that Qa-1–bound peptide is required to
generate a functional ligand for murine CD94/NKG2A,
but the capacity of this receptor to discriminate between
different Qa-1–peptide complexes remained to be ad-
dressed.
In this study, we describe experiments designed to inves-
tigate the peptide-binding motif of Qa-1
 
b
 
. The results sug-
gest that the leader peptide–derived Qdm sequence is ide-
ally suited for binding Qa-1
 
b
 
. However, our findings also
suggest that this class Ib molecule has the potential to bind a
relatively diverse repertoire of peptides in addition to Qdm.
Further experiments demonstrate that CD94/NKG2A dis-
criminates between Qa-1 complexes containing different
peptides.
 
Materials and Methods
 
Qa-1
 
b
 
 Refolding and Tetramer Formation.
 
Soluble Qa-1
 
b
 
 and
human 
 
b
 
2-microglobulin (
 
b
 
2m) were purified and refolded with
peptide as described (38). In brief, 6 liters of 
 
Escherichia coli
 
–con-
taining expression vectors were induced with isopropyl 
 
b
 
-
 
d
 
–thio-
galactopyranoside and the cells were lysed. Inclusion bodies were
purified by washing with a Triton X-100 detergent solution, and
solubilized in 8 M urea. The soluble Qa-1
 
b
 
 was folded in vitro
with 
 
b
 
2m and peptide and purified on a Pharmacia S-300 gel fil-
tration column (Amersham Pharmacia Biotech). In folding exper-
iments with random peptide libraries or peptide pools, 200-ml
folding reactions included 1 
 
m
 
M Qa-1
 
b
 
 heavy chain, 2 
 
m
 
M 
 
b
 
2m,
and 30 mg peptide. To make tetramers, refolded Qa-1
 
b
 
 was bio-
tinylated with the BirA enzyme as described (38), purified on a
UnoQ ion exchange column (Bio-Rad Laboratories), and tet-
ramerized with streptavidin-allophycocyanin (Molecular Probes,
Inc.) in a 4:1 molar ratio.
 
Peptides.
 
Peptides used in binding experiments were synthe-
sized using 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry on a
multiple peptide synthesizer (Ranin Symphony) and were labeled
as indicated through reaction with cysteine thiol groups with a
slight excess of 1-biotinamido-4-(4-[maleimidomethyl]cyclohex-
ane-carboxamido)butane (Pierce Chemical Co.). The random
and position-degenerated peptide libraries were assembled by
Fmoc-based solid-phase synthesis at the 50 
 
m
 
mol per channel
scale on a Wang resin using an Advanced ChemTech model
348O multiple peptide synthesizer. Acylation of the resin was af-
fected using a sixfold molar excess of preformed hydroxybenzo-
triazole esters of all coded Fmoc-protected amino acids (excluding 
615
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cysteine) essentially as described previously (39). A 50% molar ex-
cess of Fmoc-Val, Fmoc-Arg(Mtr), and Fmoc-Ile over other
Fmoc–amino acids was used in order to compensate for their
lower acylation rates (39, 40). After cleavage and deprotection
(Reagent K, 2 h, 25
 
8
 
C), the peptides were precipitated with di-
ethyl ether (
 
2
 
20
 
8
 
C, 4 h). The precipitate was collected by cen-
trifugation and solubilized in neat TFA, diluted with water, and
lyophilized. The lyophilized libraries were obtained in the form
of their TFA salts. Quantitative amino acid analysis and NH
 
2
 
-ter-
minal sequence analysis confirmed their expected composition
and randomness of their sequence.
 
Peptide Binding Assays.
 
Competition based peptide binding
assays were performed as described (41). In brief, refolded recom-
binant Qa-1
 
b
 
–Qdm-
 
b
 
2m (30 nM) was incubated overnight at
room temperature in 30-
 
m
 
l volumes with 0.2 
 
m
 
M biotin-
Qdm4C (AMACRTLLL), 0.01% NP-40 (United States Bio-
chemical), 10 mM citrate-phosphate buffer, pH 5.5, a cocktail of
protease inhibitors, and a range of concentrations of unlabeled
competitor peptide. Samples were pH neutralized and transferred
to 96-well plates coated with anti–human 
 
b
 
2m Ab (Immuno-
tech), washed, and incubated with 100 ng/ml of europium-labeled
streptavidin (Wallac Oy). Detection occurred at 615 nm using a
1230 ARCUS time-resolved fluorometer (LKB Wallac). IC
 
50
 
was determined by calculating the amount of unlabeled peptide
required to displace 50% of the binding of biotin-Qdm4C and
dividing by the amount of unlabeled Qdm required to do the
same.
 
Pool Peptide Sequencing.
 
Qa-1
 
b
 
 complexes were generated by
folding in vitro with random peptide libraries or peptide pools
and purified as described above. Qa-1
 
b
 
 complexes (500 
 
m
 
g) were
concentrated and peptide was eluted by dilution in 0.5 ml 0.1%
TFA/10% CH
 
3
 
CN and incubation for 30 min at 24
 
8
 
C. Eluted
peptide was separated from heavy chain and 
 
b
 
2m using a centri-
con 3 concentrator (Amicon, Inc.). Control samples were pre-
pared by mock elution. Edman degradation of the original librar-
ies and of the Qa-1
 
b
 
 bound/eluted peptides was performed in a
model Procise cLC peptide sequencer (PE Biosystems) operated
in the pulsed liquid mode essentially as described previously (39,
42). The manufacturer’s degradation chemistry cycles were used
without modification and model 610A software was used to cali-
brate the instrument, quantify the phenylthiohydantoin amino
acids, and compare the chromatograms.
Peptides eluted from Qa-1
 
b
 
 after folding with peptide pools
randomized at specific positions were directly analyzed without
further manipulation by microbore reversed-phase HPLC con-
sisting of a model 140A solvent delivery system and a model
1000S diode-array UV detector (PE Biosystems) equipped with a
2.3-
 
m
 
l flow cell. The separation was achieved using a Zorbax SB-
C18 column (1
 
 3 
 
150 mm, particle diameter 
 
z
 
5 
 
m
 
m, 300 A
pore size) equilibrated at 25
 
8
 
C in 0.1% aqueous TFA and devel-
oped at a flow-rate of 90 
 
m
 
l/min using a linear gradient of aceto-
nitrile. The column eluate was monitored at 210 and 280 nm and
evaluated using the model TurboChrom software (PE Biosys-
tems). The fractions absorbing at 210 nm were manually collected
and stored at 
 
2
 
20
 
8
 
C for sequence and mass spectrometric analy-
ses. Matrix-assisted laser desorption ionization time-of-flight mass
spectrometry analysis was performed using model Protein-TOF
or model Reflex-III mass spectrometers (Bruker Daltonics)
equipped with 337-nm nitrogen lasers; 
 
a
 
-cyano-4–hydroxycin-
namic acid (MALDI-Quality; Hewlett-Packard) was used as a
matrix. Electrospray ionization triple quadrupole mass spectrome-
try analysis was performed on a model API-3000 triple quadru-
pole mass spectrometer (PE Biosystems/Sciex) equipped with
 
MicroIonSpray electrospray source. In the positive mode, the
samples were introduced in 50% aqueous methanol containing
0.1% acetic acid.
 
Mice, Abs, and Flow Cytometry.
 
C57BL/10J mice were pur-
chased from The Jackson Laboratory and maintained by the Em-
ory University Division of Animal Resources in specific patho-
gen-free conditions. C57BL/6
 
 
 
b
 
2m
 
2
 
/
 
2
 
 (The Jackson Laboratory),
C57BL/6 K
 
b
 
2
 
/
 
2
 
, and C57BL/6 K
 
b
 
2
 
/
 
2
 
D
 
b
 
2
 
/
 
2
 
 (a gift of F. Lemon-
nier, Institut Pasteur, Paris, France) were maintained in the Uni-
versity of California at Berkeley Animal Facility. FITC-conjugated
anti-CD3
 
e
 
, PE-conjugated anti-NK1.1, and CyChrome
 
®
 
-conju-
gated anti-B220 were purchased from BD PharMingen. Spleno-
cytes were treated to lyse red blood cells before staining in PBS/
2% fetal bovine serum/0.1% sodium azide with Fc Block™ (BD
PharMingen) on ice. Fluorescence was analyzed using a FACS-
Calibur™ (Becton Dickinson).
 
IL-2–cultured NK Cells and Chromium-release Assay.
 
Spleno-
cytes pooled from 7–15 C57BL/10 mice were depleted of red
blood cells, passed though nylon wool, and cultured with 200
ng/ml rIL-2 (Chiron Corp.). The following day, cultured cells
were depleted of T cells by incubating with
 
 
 
10
 
 
 
m
 
g/ml anti-CD4
(clone GK1.5) and anti-CD8 (clone 53-6.72), followed by re-
moval of labeled cells with goat anti–rat IgG magnetic beads
(PerSeptive Biosystems). The cells were then returned to culture
with IL-2. On day 2 of culture, cells were sorted into Qa-1
 
b
 
 tet-
ramer–positive or –negative NK cells (NK1.1
 
1
 
CD3
 
2
 
) using a
FACS Vantage™ cell sorter, returned to IL-2 media, and assayed
on day 5. T2 cells expressing Qa-1
 
b
 
 (T237), a gift of Mark So-
loski (The Johns Hopkins University Medical School, Baltimore,
MD), were used as target cells. Peptides (30 
 
m
 
M) and 
 
51
 
Cr were
added to target cells overnight at room temperature, and peptide
was also included during the standard 4-h killing assay. In some
experiments, spleen cells from 12 Kb
 
2
 
/
 
2
 
 mice (
 
z
 
10-wk-old)
were cultured with IL-2 for 2 d and then stained with CD3-PE
(BD PharMingen), NK1.1-biotin, 3g2-FITC (rat anti-NKG2A/
C/E IgG2a), and streptavidin-Red670 (Caltag). The CD3-
NK1.1
 
1
 
3g2
 
1
 
cells were sorted to high purity on a Coulter EPICS
Elite cell sorter. The sorted population was returned to culture
for an additional 2 d in IL-2 before being used as effectors in
chromium-release assays. The day before the functional assay,
spleen cells from 
 
b
 
2m
 
2
 
/
 
2
 
, K
 
b
 
2
 
/
 
2
 
, and K
 
b2/2Db2/2 mice were
put into media containing 2.5 mg/ml ConA. Cells were simulta-
neously treated with or without Qdm peptide at 50 mM final
concentration. The day of the assay, the cells labeled for 1 h at
378C with 51Cr (in the presence or absence of Qdm, as appropri-
ate). Live targets were then purified on a Ficoll gradient and
washed three times before being used in a chromium-release as-
say. Qdm peptide was included in the assay for targets that had
been loaded with peptide.
Results and Discussion
Identification of Anchor Positions in Qdm. A peptide-bind-
ing immunoassay was developed using soluble recombinant
Qa-1b. Biotin-labeled Qdm was synthesized using a substi-
tuted peptide with cysteine in the P4 position providing a
thiol for selective reaction with a biotin maleimide deriva-
tive. Biotin-Qdm4C peptide was incubated with Qa-1 fol-
lowed by capture in wells coated with anti-b2m. Bound
biotin-peptide was detected with europium-streptavidin
(41). Binding, which occurs through a peptide exchange
mechanism, was saturable and specifically inhibited in the616 Peptide Specificity in Recognition of Qa-1 by NK Cells
presence of excess Qdm competitor peptide but not a con-
trol peptide (Fig. 1). Qdm4C was observed to bind to Qa-1
with affinity similar or identical to Qdm in competition as-
says. No binding was observed with a peptide labeled
through a cysteine at P3 (data not shown). Competition as-
says were used to evaluate the relative affinities of a panel of
Qdm derivatives with Lys substitutions at each position.
The concentration of competitor peptide required to in-
hibit 50% of the binding of biotin-Qdm4C was normalized
relative to Qdm. Substitutions at P2, P3, P6, and P9 re-
duced competitive binding activity below detectable levels,
indicating that these positions represent anchor residues
(Table I). A major reduction in binding was also observed
with lysine substitution at P7, whereas substitution at other
positions had little effect on binding affinity.
P9 and P2 were previously identified as dominant an-
chor residues through analysis of the capacity of Ala-substi-
tuted Qdm peptides to inhibit binding of labeled Qdm to
cell surface Qa-1b (43). Relatively small effects on binding
were observed with Ala substitutions at P3, P6, or P7 in
that study (43). This difference probably can be attributed
to the nature of the substitutions used in this study, in
which smaller nonpolar or polar side chains were replaced
by charged Lys rather than Ala. In addition, Kurepa and
Forman (43) observed that replacement of Arg with Ala at
P5 significantly reduced binding whereas the conservative
Lys substitution in this study had little effect. It is notable
that the crystal structure of a prototypic HLA class Ia leader
peptide bound to HLA-E demonstrated anchor residues at
the same five positions (P2, P3, P6, P7, and P9) identified
in this study with Qa-1 (44). The P5 Arg side chain was
observed in two conformations in the crystal structure,
fully solvent exposed or held down by a salt bridge to a res-
idue on the top of the a2 helix (44).
Analysis of the Qa-1b Peptide-binding Motif. Qa-1 was
folded in vitro with a fully random nonameric peptide li-
brary containing all natural amino acids except Cys as an
initial approach to analyze the peptide binding motif (45–
47). The acid-eluted peptide pool was subjected to Edman
sequencing, and residues with a yield of at least 150% com-
pared with the previous cycle were considered significant
and underlined in Fig. 2. A strong signal for Met and Leu
but not other amino acids was observed in cycle 2. This is
consistent with the assignment of Met at P2 in Qdm as a
dominant anchor. A Qdm derivative with Leu at P2 was
observed to bind Qa-1 with affinity similar to Qdm (Table
I), confirming that Leu can serve as an alternative P2 an-
chor. The P3 anchor appeared to be rather promiscuous
with enrichment for seven different residues. Of the five
anchor positions identified above from binding studies with
substituted Qdm peptides, the residues found in the Qdm
sequence were only identified as anchors at P2, P6, and P7
from pool sequence analysis. Enrichment for selected
amino acids was also observed at each nonanchor position.
Among these, the Qdm residue Arg was enriched at P5.
The significance of preference for specific residues at
nonanchor positions remains uncertain. However, pre-
ferred residues at nonanchor positions are commonly ob-
served in this type of study (45–48). The absence of enrich-
ment for Leu at P9 (Fig. 2) was of concern because this was
identified as the dominant anchor by Kurepa and Forman
Figure 1. Peptide binding to Qa-1b. Soluble recombinant Qa-1b (30
nM) was incubated overnight at room temperature in duplicate with 0.2
mM biotin-Qdm4C and the indicated concentrations of unlabeled com-
petitor peptide. Qa-1b was then captured with anti-b2m Ab and bound
biotinylated peptide was detected with europium-streptavidin fluores-
cence, indicated as counts per second (cps). The dashed line indicates
quantity of bound biotin-Qdm4C in the absence of competitor peptide.
The polyoma virus peptide MT(389–397), RRLGRTLLL, binds Dk
with high affinity (reference 41).
Table I. Competition for Binding of Biotin-Qdm4C to Qa-1b by 
Qdm Analogues
Competitor peptide Peptide sequence IC50
Qdm AMAPRTLLL 1
Qdm P1 KMAPRTLLL 8
Qdm P2 AKAPRTLLL .1,000
Qdm P3 AMKPRTLLL .1,000
Qdm P4 AMAKRTLLL 6
Qdm P5 AMAPKTLLL 5
Qdm P6 AMAPRKLLL .1,000
Qdm P7 AMAPRTKLL 200
Qdm P8 AMAPRTLKL 2
Qdm P9 AMAPRTLLK .1,000
Qdm P2T ATAPRTLLL 73
Qdm P2L ALAPRTLLL 2
Dk signal AMVPRTLLL 2
Qa-1 signal LFAHLLQLL 115
CD1.1 signal YLPWLLLWA .300
Influenza NP FLARSALIL 9
hCMV UL40 VMAPRTLIL 1
NP, nucleoprotein; h, human.617 Kraft et al.
(43) and its importance was confirmed in this study (Table
I). The COOH-terminal position is in general a dominant
anchor for class I MHC–binding peptides with a high de-
gree of selectivity for one or a few chemically related (usu-
ally hydrophobic or positively charged) residues (45, 48).
To further investigate peptide-binding specificity, Qa-1
was folded with a series of peptide pools each containing
the Qdm sequence randomized at a single position. Se-
quencing and amino acid analysis of the initial peptide
pools demonstrated similar representation of each amino
acid (except cysteine, which was excluded in synthesis) at
the randomized positions. Representative reversed-phase
HPLC profiles for the pool randomized at P9, before and
after folding and elution from Qa-1, are shown in Fig. 3.
HPLC fractions were collected and predominant eluted
peptides were identified by mass spectrometry and/or Ed-
man sequencing and quantified by integration of HPLC
peak area (l 5 210 nm) (Table II). Among 19 peptides in
the pool randomized at P2, those with hydrophobic amino
acids Met, Ile, or Leu accounted for .80% of the peptides
eluted from Qa-1. The most stringent specificity was ob-
served with the pool randomized at P9; a single peptide
containing Leu at P9 accounted for 85% of eluted peptide.
A variety of amino acids was preferred at each of the other
positions tested. Strikingly, the residue found in each posi-
tion in the natural Qdm sequence was highly enriched
among peptides eluted from Qa-1 for each peptide pool
that was tested (Table II). These data support the conclu-
sion that Qdm has an ideal or near-ideal primary structure
for binding to Qa-1b.
The results from the above experiment with limited
peptide pools (Table II) are in reasonable agreement with
those obtained using the fully random peptide library (Fig.
2) with respect to amino acids preferred at P2, P5, P6, and
P7. Preference for Met and Leu at P2 was identified
through both approaches. Similarly, common preferences
for Thr at P6 and Pro, Ile, and Leu at P7 were identified.
By contrast, few common amino acids were identified as
preferred at P3 with the two approaches. It is evident,
however, that there is little stringency at this position. The
observation that Leu is highly preferred among Qdm pep-
tides randomized at P9 markedly contrasts with the results
of our study with the fully random peptide library that
showed no enrichment for Leu at this position. This differ-
ence might be accounted for by direct or indirect coopera-
tive interactions between amino acid residues at different
positions. In the context of the Qdm sequence, the P9 po-
sition could be constrained, imposing a stringent require-
ment for Leu at this position. In the context of other
sequences, this preference could conceivably change. Al-
ternatively, the reduced signal attributed to the “washout”
that is inevitably associated with later cycles of Edman deg-
radation may have obscured a preference for Leu at P9 in
our experiments with the fully random library. Both exper-
imental approaches indicated that Arg and Tyr are pre-
ferred at the putative nonanchor P5 position. Thus, side
chains at this position can clearly influence association with
Qa-1, but whether this side chain is buried (acting as a clas-
Figure 2. Pool sequencing of peptides
eluted from soluble Qa-1b refolded with a
random nonameric library. Recombinant
Qa-1b heavy chain was refolded in the pres-
ence of a random nonameric library and
human b2m. Free peptide and b2m were
removed by gel filtration, and bound pep-
tide was eluted and analyzed by Edman
degradation. The yield of each amino acid
in pmol (indicated by single letter code) is
shown. Positions where the yield of amino
acid is at least 150% of the previous cycle
are underlined.
Figure 3. Selective incorporation of peptides during in vitro folding of
Qa-1b. Folding reactions were carried out in the presence of pools of
Qdm peptides each randomized at a single position. After purification,
peptide was eluted from the Qa-1 complexes and analyzed by reversed-
phase HPLC, mass spectrometry, and Edman sequencing. Shown are
HPLC profiles of the Qdm library randomized at P9 and the peptides
eluted from Qa-1 that was folded in the presence of this library. *Peak
identified as peptide with Leu at P9 (Qdm).618 Peptide Specificity in Recognition of Qa-1 by NK Cells
 
Table II. Amino Acid Preference at Specific Positions in
Qdm Libraries
Position* Predominant residue Percentage‡
2 Met 32
Ile 29
Leu 20
Met(O), Glu 12
Val 4.5
Unassigned 2.5
3 Ala 23
Ser 1 Thr 19
Ile 13
Val 13
Leu 11
Met 11
Gln 7
Unassigned 3
5 Ser 26
Arg 1 Asn 21
Tyr 12
His 10
Ala 9.5
Lys 7.8
Thr 7.3
Unassigned 6.4
6 Ala 27
Thr 26
Ser 17
Val 7
His 6
Phe 3.8
Tyr 3.7
Unassigned 9.5
7 Pro 25
Met 22
Leu 20
Ile 20
Val 5.1
Phe 3.7
Unassigned 4.2
9 Leu 85
Val 2.4
Met 1.8
Phe 1.7
Unassigned 9.1
*Qa-1b was folded in the presence of pools of Qdm peptides each ran-
domized at the indicated position.
‡Percentage of peptide eluted from Qa-1b containing the indicated
amino acid.
sical anchor) or is solvent exposed (44), influencing binding
though surface interactions, remains to be determined.
We performed an additional experiment to explore the
possibility that Qa-1b may have a capacity to bind a diverse
repertoire of peptides despite its preference for the Qdm
sequence. A peptide library with a complexity of z500 se-
quences was synthesized by coupling mixtures of amino ac-
ids at P3, P5, P6, and P7 and fixing the other positions
with the amino acids found in Qdm. Amino acids included
in the mixtures were selected based on preferred residues
identified in the experiments described above. Qa-1 was
folded in the presence of this library and eluted peptides
were analyzed by HPLC; selected peaks were sequenced. A
highly diverse set of peptides was observed to associate with
Qa-1 under these conditions (data not shown). In addition,
four peptides were analyzed from a sequence database
search based on the motif identified from the data pre-
sented in Table II. One of these four, from influenza nu-
cleoprotein, was observed to bind with relatively high af-
finity to Qa-1b (Table I). We conclude that, although Qdm
has a near-ideal sequence for binding Qa-1, this class Ib
protein has the potential to assemble with a relatively di-
verse repertoire of peptides.
The Role of H-2Db as a Source of Leader Peptide for Inhibi-
tion of NK Lysis. We reported previously that addition of
Qdm peptide was required to inhibit lysis of transfected
human T2 B cell targets expressing high levels of Qa-1b in
experiments with CD94/NKG2A-positive NK effector
cells (23). Endogenous leader peptides were not presented
by Qa-1 molecules because T2 cells do not express TAP
and leader peptide presentation by Qa-1 requires TAP
(11). It is unknown whether these cells express “empty”
Qa-1 molecules or Qa-1 associated with some undefined
peptides loaded through a TAP-independent mechanism.
However, it is clear that Qa-1 molecules expressed in T2
cells were unable to serve as a functional ligands for CD94/
NKG2A in the absence of exogenous Qdm (23). The ob-
servation that no increase in Qa-1 expression was observed
in cells cultured with Qdm suggested that there is peptide
dependency in recognition of Qa-1 by the inhibitory re-
ceptor (23).
Experiments were performed to further investigate the
role of Qdm in generating functional ligand for CD94/
NKG2A. In H-2b cells, the only known source of Qdm is
Db since Kb does not have the correct motif in its leader se-
quence. The role of Db in inhibition of NK lysis was inves-
tigated in chromium-release assays with targets expressing
Qa-1 in the presence or absence of Db. IL-2–activated
CD94/NKG2-positive Kb2/2 NK cells were used as effec-
tors. A small degree of lysis of autologous Kb2/2 target cells
was observed (Fig. 4). This may be due to partial reversal of
self-tolerance, which has sometimes been observed when
NK cells are cultured in high concentrations of IL-2 (49).
However, the Db molecule on Kb2/2 targets clearly inhib-
ited lysis because Kb2/2Db2/2 targets were lysed much bet-
ter than Kb2/2 targets. Confirmation that the leader peptide
could inhibit NK cells was obtained by incubating Kb2/2
Db2/2 targets with exogenous Qdm; this treatment resulted619 Kraft et al.
in potent inhibition of NK-mediated lysis as shown in a
previous study with Kb2/2D2/2 targets (50). The effect of
Qdm appeared to depend on Qa-1 expression since killing
of b2m2/2 targets, which do not express Qa-1, was not in-
hibited by exogenous Qdm peptide (Fig. 4). Importantly,
killing of Kb2/2Db2/2 targets was indistinguishable from
killing of b2m2/2 targets, suggesting that Db is essential for
inhibition of NK cells under our experimental conditions.
These results extend previous observations (50, 51) support-
ing the conclusion that Db is the only source of peptide that
can bind Qa-1 in ConA-activated spleen cells to generate a
functional ligand for CD94/NKG2A inhibitory receptors.
Specificity of CD94/NKG2A Receptors for Qa-1–associated
Peptide. The above experiments and previous studies (23)
clearly indicated that Qa-1b–Qdm complexes can serve as
ligands for CD94/NKG2A, but the degree to which the
receptor is able to discriminate between Qa-1 complexes
containing different peptides remained unknown. This
question became particularly relevant in light of the obser-
vation that Qa-1 has the potential to bind a relatively di-
verse repertoire of peptides. This issue was further investi-
gated by generating fluorescent soluble tetrameric Qa-1b
complexes bearing Qdm peptides with substitutions at dif-
ferent nonanchor positions. As previously reported (23),
tetramers generated from Qa-1b folded with Qdm peptide
bind to 40–50% of splenic NK cells (Fig. 5 A). Staining
with tetramers containing the Dk leader sequence, which
contains Val instead of Ala at P3, was somewhat reduced
compared with Qdm, yet a substantial fraction of NK cells
clearly binds this reagent. By contrast, little if any staining
was observed with tetramers containing substituted Qdm
peptides with Lys at P1, P4, P5, or P8. To confirm the
specificity of NK cell staining, a parallel experiment was
performed with transfectants expressing high levels of
CD94/NKG2A. No tetramer staining was observed with
control cells that did not express CD94/NKG2A het-
erodimer (23). Qa-1 tetramers containing Qdm or the Dk
leader peptide stained the transfectants uniformly (Fig. 5 B).
No staining was observed with peptides containing substi-
tutions at P4, P5, or P8. The transfectants uniformly re-
acted with tetramer containing the P1-substituted peptide
but the mean fluorescence intensity was substantially re-
duced, suggesting that this substitution may reduce affinity
for CD94/NKG2A. The increased staining of transfected
cells compared with splenic NK cells with tetramer con-
taining the P1-substituted peptide probably can be attrib-
uted to the greater level of expression of CD94/NKG2A
on the transfectants.
Functional experiments were done to confirm the tet-
ramer staining data. As reported previously (23), exogenous
Figure 4. Db is the only cellular source of peptide capable of binding to
Qa-1b and inhibiting NK lysis. IL-2–cultured CD3-NK1.1 plus NKG2
plus splenocytes from Kb2/2 mice were used as effector cells. Spleen cells
from B6 b2m2/2, B6 Kb2/2, and B6 Kb2/2Db2/2 mice were cultured
overnight with ConA (2.5 mg/ml), labeled for 1 h at 378C with 51Cr, and
used as targets in a standard 4-h 51Cr-release assay. Qdm peptide (50 mM)
was included during culture with ConA, labeling, and lysis phases of the
assay for the indicated groups of target cells.
Figure 5. Binding of Qa-1b tetramers containing substituted Qdm pep-
tides to CD94/NKG2A. (A) Flow cytometry profiles were obtained using
CD32B2202 C57BL/10 splenocytes stained with anti-NK1.1 and Qa-1b
tetramers, prepared with Qdm or substituted Qdm peptides containing
Lys at the indicated position. The Dk leader peptide differs from Qdm,
containing a Val instead of Ala at P3. Numbers in the upper right hand
corner correspond to percentage of NK1.11 cells that are tetramer posi-
tive. (B) Chinese hamster ovary transfectants expressing CD94 and
NKG2A were stained with Qa-1b tetramers (solid line) or streptavidin-
allophycocyanin (dotted line).620 Peptide Specificity in Recognition of Qa-1 by NK Cells
Qdm peptide is able to markedly inhibit killing of T2 cells
expressing Qa-1b in assays with activated NK cells sorted
for expression of CD94/NKG2A using Qa-1–Qdm tet-
ramers (Fig. 6). Qdm does not inhibit lysis mediated by tet-
ramer-negative NK cells that lack expression of CD94/
NKG2A. Substantial inhibition was observed with the P1-
substituted Qdm variant (Fig. 6). Thus, the P1 substitution
had little or no functional consequences despite tetramer
staining data suggesting that this substitution may have re-
duced receptor binding affinity. The Dk leader peptide also
inhibited target cell lysis, although the extent of inhibition
was somewhat reduced compared with Qdm (Fig. 6). The
Val substitution at P3 in the Dk leader is the only known
polymorphism in the corresponding leader sequences of
murine H-2D and H-2L molecules. Therefore, our results
are consistent with the conclusion that functional ligands
for CD94/NKG2 can be generated in mice of all haplo-
types. No inhibition of killing by tetramer-positive NK
cells was observed with substituted Qdm peptides contain-
ing Lys at P5 or P8, or with the influenza peptide that had
previously been determined to bind Qa-1 with relatively
high affinity (Table I).
Together, the tetramer binding data and the functional
experiments provide strong evidence that CD94/NKG2A
has a high degree of specificity for the primary structure of
peptide bound to its Qa-1 ligand. The effect observed with
substitutions at P4, P5, or P8 suggests that the receptor may
directly contact the side chains of residues in these posi-
tions, consistent with a binding interface that may overlap
that used for recognition by T cell antigen receptors. This
contrasts with the interaction sites recently defined by the
crystal structure of the Ly49A NK inhibitory receptor
bound to H-2Dd (52). Two sites were identified that are
spatially distinct from the T cell receptor binding site, ex-
plaining the previous observation that Ly49A recognizes
MHC class I–peptide complexes independent of peptide
composition (53). There is some evidence, however, that
Ly49C and Ly49I may have some degree of peptide selec-
tivity (54–56) The extent to which CD94/NKG2A can
discriminate between peptides with chemically conserva-
tive substitutions at anchor or solvent-exposed positions re-
mains to be determined. Substitution of smaller nonpolar
residues at P4 or P8 with positively charged Lys represents
a relatively substantial change in local surface chemistry. In
addition, replacement of Pro at P4 may have a significant
effect because of the loss of the conformational constraint
uniquely associated with Pro. However, a conservative Arg
to Lys substitution at P5 also abrogates receptor binding
and function. The P5 position may play a particularly im-
portant role in receptor recognition.
Several studies suggest that sequence variation in HLA-
E–bound leader peptides can influence affinity for human
CD94/NKG2 receptors. Llano et al. reported that a leader
peptide from HLA-Cw7 with Ala instead of Thr at P6 was
unable to inhibit NK killing despite good binding to HLA-E
as measured by stabilization of HLA-E in TAP-deficient
721.221 cells (35). Polymorphisms in human leader peptide
residues P1 (Val, Ile), P7 (Leu, Val), and P8 (Leu, Ile, Val,
and Phe) did not affect inhibitory activity, consistent with
previous results (27–29, 35). Evidence was also provided
suggesting that the HLA-G leader peptide, containing Phe
at P8, may be preferentially recognized by the activating
receptor CD94/NKG2C compared with other leader pep-
tides (35). Brooks et al. reported that receptor binding was
reduced with HLA-E complexes containing the Cw7
leader with Ala at P6 (36). In contrast to the results of
Llanno et al. (35), this peptide was observed to inhibit NK
killing, but only if included in culture throughout the assay
(36). It is possible that HLA-E complexes containing the
Cw7 leader peptide may be relatively unstable, explaining
the apparent discrepancy. An EBV peptide that had previ-
ously been shown to bind HLA-E (57) was unable to form
a ligand for soluble CD94/NKG2A, nor did it inhibit kill-
ing by NK cells (36). Vales-Gomez et al. demonstrated
peptide-dependent differences in the binding kinetics of
soluble HLA-E to soluble CD94/NKG2A and CD94/
NKG2C (37). For both receptors, the highest affinity inter-
actions were observed with HLA-E containing the leader
peptide from HLA-G (Phe at P8). Differences in the bind-
ing affinities of a panel of HLA-E complexes containing
leader peptides with sequence variation in P2, P3, P6, or
P8 further demonstrated specificity for bound peptide (37).
Together, the above studies suggest that the human CD94/
NKG2 receptors can discriminate between HLA-E com-
plexes containing different leader peptides. The structural
basis for discrimination and functional consequences re-
main to be further characterized.
The specificity of CD94/NKG2A for both Qa-1 and the
Figure 6. Inhibition of NK cell killing by Qa-1b peptide complexes.
IL-2–cultured CD32NK1.11 NK cells were sorted into Qa-1b–Qdm tet-
ramer positive and negative populations. After further culture, the acti-
vated NK effector cells were tested for their ability to kill Cr51-labeled
Qa-1b–transfected T2 cell (T237) targets in the presence of the indicated
peptides. Targets were incubated at room temperature overnight with 30
mM peptide and 51Cr. Peptide (30 mM) was included in the killing assay.621 Kraft et al.
primary structure of the Qa-1–bound peptide could make
it more difficult for viruses or other microbial pathogens to
evade recognition by the immune system. Viral proteins
that inhibit components of the class I antigen processing
pathway to evade recognition by CD81 T cells (58) could
make an infected cell sensitive to lysis by NK cells if the
supply of either Qa-1 or Qdm were also disrupted. Inhibi-
tion of TAP activity may not inhibit cell surface expression
of the Qa-1 protein (23) but it would certainly inhibit ex-
pression of the Qa-1–Qdm complexes (11) required for
recognition by inhibitory receptors. To avoid NK recogni-
tion, it would be necessary for a virus to provide an alterna-
tive peptide capable of binding Qa-1, loaded through a
TAP-independent mechanism and mimicking the primary
structure of Qdm for recognition by CD94/NKG2A. Just
such a mechanism has recently been described by Tomasec
et al., who reported that expression of the human cytomeg-
alovirus glycoprotein UL40 can upregulate expression of
HLA-E in TAP-deficient cells and protect targets from NK
lysis (59). UL40 contains a sequence in its signal peptide ex-
actly identical to a nonameric human HLA-C leader pep-
tide known to bind HLA-E. Murine hepatitis virus E3 gly-
coprotein contains a sequence identical to Qdm in its leader
peptide (60). It is possible that this virus has developed a
similar mechanism for escape from NK recognition during
coevolution with its murine hosts. Given evidence pre-
sented here that Qa-1 has a capacity to bind a relatively di-
verse repertoire of peptides, it is interesting to speculate that
virus-encoded peptides could compete with Qdm for bind-
ing to Qa-1 in infected cells without generating an appro-
priate ligand for CD94/NKG2A inhibitory receptors. This
could provide a novel mechanism for NK cell activation.
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